132 related articles for article (PubMed ID: 14992162)
1. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethinyl estradiol-cyproterone acetate treatment.
Luboshitzky R; Shen-Orr Z; Herer P; Nave R
Gynecol Endocrinol; 2003 Dec; 17(6):441-7. PubMed ID: 14992162
[TBL] [Abstract][Full Text] [Related]
2. Cyproterone acetate-ethinyl estradiol treatment alters urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women.
Luboshitzky R; Herer P; Shen-Orr Z
Neuro Endocrinol Lett; 2002 Aug; 23(4):309-13. PubMed ID: 12195232
[TBL] [Abstract][Full Text] [Related]
3. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
Luboshitzky R; Herer P; Shen-Orr Z
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
5. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of low dose flutamide plus Diane-35 in the treatment of idiopathic hirsutism and polycystic ovary syndrome.
Boztosun A; Açmaz G; Ozturk A; Müderris II
Ginekol Pol; 2013 Apr; 84(4):258-62. PubMed ID: 23700857
[TBL] [Abstract][Full Text] [Related]
7. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
Feng W; Jia YY; Zhang DY; Shi HR
Gynecol Endocrinol; 2016; 32(2):147-50. PubMed ID: 26507097
[TBL] [Abstract][Full Text] [Related]
8. Increased 6-sulfatoxymelatonin excretion in women with polycystic ovary syndrome.
Luboshitzky R; Qupti G; Ishay A; Shen-Orr Z; Futerman B; Linn S
Fertil Steril; 2001 Sep; 76(3):506-10. PubMed ID: 11532473
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
11. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
Frölich M; Lachinsky N; Moolenaar AJ
Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
13. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
Wu H; Ruan X; Jin J; Mueck AO
Gynecol Endocrinol; 2015 Jul; 31(7):548-51. PubMed ID: 26004979
[TBL] [Abstract][Full Text] [Related]
14. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism.
Sahin Y; Dilber S; Keleştimur F
Fertil Steril; 2001 Mar; 75(3):496-500. PubMed ID: 11239530
[TBL] [Abstract][Full Text] [Related]
16. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
[TBL] [Abstract][Full Text] [Related]
17. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.
Sert M; Tetiker T; Kirim S
Acta Med Okayama; 2003 Apr; 57(2):73-6. PubMed ID: 12866746
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
20. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
Chung JP; Yiu AK; Chung TK; Chan SS
J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
